ArticleBMC nephrology2026
Metabolomic profiling in IgA nephropathy: urinary and salivary biomarker insights.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundImmunoglobulin A Nephropathy (IgAN) is the most common primary glomerulonephritis, often leading to end-stage kidney disease in 20-40% of cases. Despite extensive research on urinary and serum metabolomics, salivary metabolomics remains unexplored. This study investigates metabolomic alterations in IgAN using both salivary and urinary analyses and examines potential correlations between these biofluids.
methodsMetabolomic profiling was performed using liquid chromatography-high resolution mass spectrometry (LC-HRMS) on saliva and urine samples from 16 IgAN patients and 13 matched controls. Data were processed using TidyMass and MetaboAnalyst, with metabolite annotation via HMDB, MassBank and MoNA. Pathway analysis was conducted using the KEGG database, with statistical significance set at p < 0.05 or FDR < 0.05.
resultsSalivary analysis identified 42 metabolites, with four significantly altered in IgAN patients. Picric acid, Buphedrone and Deoxyadenosine were elevated, while N-Acetylneuraminic acid was reduced, implicating ABC transporters, purine metabolism and neurotransmitter pathways. Urinary analysis revealed 138 metabolites, with 14 significantly altered, primarily affecting the pentose phosphate pathway. No significant correlation was observed between urinary and salivary metabolomic profiles.
conclusionThough urinary and salivary metabolomes showed distinct alterations, our study only supported N-Acetylneuraminic acid as a potential IgAN biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.